Innate Pharma (IPH) - Total Assets
Based on the latest financial reports, Innate Pharma (IPH) holds total assets worth €62.72 Million EUR (≈ $73.33 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Innate Pharma cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Innate Pharma - Total Assets Trend (2003–2025)
This chart illustrates how Innate Pharma's total assets have evolved over time, based on quarterly financial data. Explore IPH long-term investment intensity to see how much of total assets are deployed in long-term investments.
Innate Pharma - Asset Composition Analysis
Current Asset Composition (December 2025)
Innate Pharma's total assets of €62.72 Million consist of 74.5% current assets and 25.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €28.09 Million | 44.8% |
| Accounts Receivable | €12.40 Million | 19.8% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €4.36 Million | 7.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2003–2025)
This chart illustrates how Innate Pharma's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see IPH company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Innate Pharma's current assets represent 74.5% of total assets in 2025, an increase from 0.0% in 2003.
- Cash Position: Cash and equivalents constituted 44.8% of total assets in 2025, up from 2.0% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2003.
- Asset Diversification: The largest asset category is cash and equivalents at 44.8% of total assets.
Innate Pharma Competitors by Total Assets
Key competitors of Innate Pharma based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $2.25 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Hugel Inc
KQ:145020
|
Korea | ₩1.13 Trillion |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
USA | $553.60 Million |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Absci Corp
NASDAQ:ABSI
|
USA | $195.59 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Innate Pharma - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.27 | 2.60 | 3.71 |
| Quick Ratio | 1.27 | 2.60 | 3.64 |
| Cash Ratio | 0.77 | 2.01 | 0.00 |
| Working Capital | €10.06 Million | €52.76 Million | €126.64 Million |
Innate Pharma - Advanced Valuation Insights
This section examines the relationship between Innate Pharma's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 20.99 |
| Latest Market Cap to Assets Ratio | 1.84 |
| Asset Growth Rate (YoY) | -43.5% |
| Total Assets | €62.72 Million |
| Market Capitalization | $115.22 Million USD |
Valuation Analysis
Above Book Valuation: The market values Innate Pharma's assets above their book value (1.84x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Innate Pharma's assets decreased by 43.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Innate Pharma (2003–2025)
The table below shows the annual total assets of Innate Pharma from 2003 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €62.72 Million ≈ $73.33 Million |
-43.53% |
| 2024-12-31 | €111.06 Million ≈ $129.84 Million |
-39.71% |
| 2023-12-31 | €184.19 Million ≈ $215.34 Million |
-11.39% |
| 2022-12-31 | €207.86 Million ≈ $243.01 Million |
-22.29% |
| 2021-12-31 | €267.50 Million ≈ $312.73 Million |
-12.99% |
| 2020-12-31 | €307.42 Million ≈ $359.41 Million |
-23.40% |
| 2019-12-31 | €401.36 Million ≈ $469.23 Million |
-11.05% |
| 2018-12-31 | €451.22 Million ≈ $527.52 Million |
+76.93% |
| 2017-12-31 | €255.02 Million ≈ $298.15 Million |
-9.43% |
| 2016-12-31 | €281.58 Million ≈ $329.19 Million |
-7.97% |
| 2015-12-31 | €305.96 Million ≈ $357.69 Million |
+237.36% |
| 2014-12-31 | €90.69 Million ≈ $106.03 Million |
+62.29% |
| 2013-12-31 | €55.88 Million ≈ $65.33 Million |
+15.71% |
| 2012-12-31 | €48.30 Million ≈ $56.46 Million |
-19.65% |
| 2011-12-31 | €60.11 Million ≈ $70.27 Million |
+25.20% |
| 2010-12-31 | €48.01 Million ≈ $56.13 Million |
-25.24% |
| 2009-12-31 | €64.22 Million ≈ $75.08 Million |
+5.52% |
| 2008-12-31 | €60.86 Million ≈ $71.15 Million |
-3.63% |
| 2007-12-31 | €63.15 Million ≈ $73.83 Million |
-8.81% |
| 2006-12-31 | €69.25 Million ≈ $80.97 Million |
+179.63% |
| 2005-12-31 | €24.77 Million ≈ $28.96 Million |
-16.07% |
| 2004-12-31 | €29.51 Million ≈ $34.50 Million |
+44.82% |
| 2003-12-31 | €20.38 Million ≈ $23.82 Million |
-- |
About Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated t… Read more